Gr-ADI consortium announced Philip Fowler, 22nd January 2026 Pleased and excited to be a small part of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) consortium which was announced today. Gr-ADI is a join initiative between the Gates Foundation, Novo Nordisk Foundation, and Wellcome. Our project is headed by Dr Annette von Delft and you can read more about it here! Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Related antimicrobial resistance grants
antimicrobial resistance New paper: automatically and reproducibly building a catalogue bedaquline resistance-associated variants 18th June 20251st July 2025 Dylan Adlard‘s paper describing how we can rapidly automatically build catalogues of bedaquiline resistance-associated variants… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance BashTheBug at the Science Museum 29th March 20175th August 2018 A group of us from Modernising Medical Microbiology went to the Science Museum in London… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance New preprint: compensatory mutations are associated with increased growth in resistant samples of M. tuberculosis. 22nd June 20238th December 2023 In this preprint, Viki Brunner shows how, using the large CRyPTIC dataset, she can recapitulate… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More